Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

926 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A tale of two atria.
Kanjwal K, Khaliq A, Grubb BP, Foster W, Kanjwal Y. Kanjwal K, et al. Among authors: foster w. Indian Pacing Electrophysiol J. 2010 Mar 5;10(3):156-7. Indian Pacing Electrophysiol J. 2010. PMID: 20234814 Free PMC article.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00548-8. doi: 10.1016/S0140-6736(24)00548-8. Online ahead of print. Lancet. 2024. PMID: 38763154 Free article.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 May 16:S0140-6736(24)00549-X. doi: 10.1016/S0140-6736(24)00549-X. Online ahead of print. Lancet. 2024. PMID: 38763153 Free article.
Large language models approach expert-level clinical knowledge and reasoning in ophthalmology: A head-to-head cross-sectional study.
Thirunavukarasu AJ, Mahmood S, Malem A, Foster WP, Sanghera R, Hassan R, Zhou S, Wong SW, Wong YL, Chong YJ, Shakeel A, Chang YH, Tan BKJ, Jain N, Tan TF, Rauz S, Ting DSW, Ting DSJ. Thirunavukarasu AJ, et al. Among authors: foster wp. PLOS Digit Health. 2024 Apr 17;3(4):e0000341. doi: 10.1371/journal.pdig.0000341. eCollection 2024 Apr. PLOS Digit Health. 2024. PMID: 38630683 Free PMC article.
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG. Mestre-Ferrandiz J, et al. Among authors: foster w. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr;24(4):509-519. doi: 10.1080/14737167.2024.2310684. Epub 2024 Feb 12. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38284223
926 results